<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Japanese encephalitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Japanese encephalitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Japanese encephalitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan L Hills, MBBS, MTH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tom Solomon, FRCP, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is the most important cause of viral encephalitis in Asia based on its frequency and severity. With the near eradication of poliomyelitis, JEV is now the leading cause of childhood viral neurological infection and disability in Asia [<a href="#rid1">1</a>]. JEV is closely related to West Nile, St. Louis encephalitis, and Murray Valley encephalitis viruses [<a href="#rid2">2</a>].</p><p>About 68,000 cases of Japanese encephalitis (JE) are estimated to occur each year. JEV is endemic throughout most of Asia and parts of the western Pacific. For travelers to Asia, the risk of JE is very low but varies based on season, destination, duration, and activities [<a href="#rid3">3</a>]. The estimated incidence of JE among travelers to Asia from nonendemic countries is &lt;1 case per 1 million travelers. Risk is likely to be higher for individuals with longer duration of travel or whose plans include extensive outdoor activities in rural areas [<a href="#rid3">3</a>]. Between 1973 and 2020, 88 cases of JE among individuals from nonendemic countries were reported [<a href="#rid3">3</a>]. Since a JE vaccine became available in the United States in 1993, only 13 cases of JE were reported among United States travelers through 2020 [<a href="#rid4">4,5</a>].</p><p>Most human JEV infections are asymptomatic or cause a nonspecific febrile illness. Fewer than 1 percent of JEV infections results in symptomatic neuroinvasive disease [<a href="#rid6">6</a>]. However, when neurologic disease does occur, it is usually very severe with a high case-fatality rate; among survivors, neurological sequelae are common. All travelers to JEV-endemic countries should be given advice on measures to prevent JE, and JE should be considered among the differential diagnoses for patients with suspected neurological infection who have returned from recent travel in a JEV-endemic country in Asia or the Western Pacific region.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>JE is endemic throughout most of Asia and parts of the Western Pacific region (<a class="graphic graphic_figure graphicRef52734" href="/d/graphic/52734.html" rel="external">figure 1</a>). During 2022, cases were reported for the first time in eastern and southern states of Australia, much further south than where JEV transmission had previously been detected [<a href="#rid7">7</a>]. Within the JE-endemic region, there are two typical patterns of transmission:</p><p class="bulletIndent1"><span class="glyph">●</span>In areas with temperate climates (including China, Japan, South Korea, Nepal, northern Vietnam, and northern India), most cases occur over a period of several months when the weather is warmest, usually after the monsoons begin or associated with heavy rainfall [<a href="#rid2">2,8,9</a>]. The peak months of transmission and the length of the season vary from place to place. There are sometimes large, explosive outbreaks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In areas with tropical climates (including Cambodia, Indonesia, southern Vietnam, and southern Thailand), there is year-round transmission. An increase in cases may be observed during the rainy season [<a href="#rid10">10,11</a>].</p><p></p><p>In endemic areas, JE typically affects children &lt;15 years of age; by early adulthood, the majority of the population has protective immunity following natural exposure to JEV as a result of ongoing environmental transmission [<a href="#rid12">12</a>]. However, when the virus enters new geographic areas where there is no immunity, JE affects both adults and children [<a href="#rid10">10</a>]. In regions where childhood immunization programs have been introduced, the age distribution of disease shifts to older ages [<a href="#rid9">9,13</a>]. Among immunologically naïve travelers visiting JEV-endemic regions, the disease can affect individuals at any age [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3"><span class="h1">TRANSMISSION</span><span class="headingEndMark"> — </span>JEV is transmitted in an enzootic cycle involving mosquitoes and vertebrate amplifying hosts, primarily pigs and wading birds. Humans are incidental and dead-end hosts in the JEV transmission cycle as they do not develop sufficiently high viremia to infect feeding mosquitoes. Therefore, mosquitoes do not transmit the virus directly from one person to another person.</p><p>Mosquitoes of the <em>Culex vishnui</em> subgroup, particularly <em>Culex tritaeniorhynchus</em>, are the major vectors of JEV, although JEV has been isolated from over 30 mosquito species [<a href="#rid14">14</a>]. <em>C. tritaeniorhynchus</em> commonly breeds in rice fields, marshes, and other shallow pools of water. It is an evening and night-time biting mosquito and mainly feeds outdoors, preferentially on large animals and birds and only infrequently on humans.</p><p>Pigs and wading birds, such as herons and egrets, are the most important hosts for maintenance and amplification of JEV. Pigs are a key host as they develop high levels of viremia, and in Asia, large numbers of pigs are frequently kept near human dwellings. In addition, the population of susceptible pigs is replenished regularly because of commercial slaughtering [<a href="#rid10">10</a>]. JEV infection in pigs is usually subclinical, but gestational infection can result in abortions and stillbirths [<a href="#rid6">6</a>]. The strong epidemiological link with pigs in the JEV transmission cycle has sometimes led to the misconception that areas without pigs are likely to be free of disease. However, transmission in such areas has also been documented, likely secondary to infection in wading birds [<a href="#rid11">11</a>].</p><p>The risk for JEV infection is highest in rural, agricultural areas of Asia, as all the elements of the enzootic transmission cycle are in close proximity to humans. However, Japanese encephalitis cases are occasionally reported from urban or peri-urban areas [<a href="#rid15">15</a>]. A small number of cases of transmission via non-mosquito-borne routes have been reported; these include transplacental transmission, transfusion, laboratory exposure, and possibly organ transplantation [<a href="#rid16">16-18</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The most commonly recognized clinical presentation of JEV infection is acute encephalitis. Milder forms of disease such as aseptic meningitis or nonspecific febrile illness with headache also occur [<a href="#rid1">1</a>]. After an incubation period of 5 to 15 days, initial symptoms are usually nonspecific and may include fever, diarrhea, and rigors followed by headache, vomiting, and generalized weakness. Over the next few days, mental status changes, focal neurologic deficits (including paresis, hemiplegia, tetraplegia, or cranial nerve palsies), and/or movement disorders develop [<a href="#rid6">6,19</a>]. Many patients lapse into coma and some require ventilatory assistance.</p><p>In some patients, the initial presentation may consist of abnormal behavior or acute psychosis, leading to potential misdiagnosis. For example, during the Korean War in the 1950s, some American soldiers presenting with JE were thought initially to have "war neurosis" [<a href="#rid20">20</a>].</p><p>Seizures (usually generalized tonic-clonic) are very common, especially among children. In some children, subtle motor seizures occur and may present with twitching of a digit, eye deviation, or irregular breathing. These may be missed without electroencephalogram monitoring [<a href="#rid21">21</a>]. A very distinctive clinical presentation of JE is a Parkinsonian syndrome resulting from extrapyramidal involvement; findings include dull, flat, mask-like facies with unblinking eyes, tremor, and cogwheel rigidity [<a href="#rid19">19</a>].</p><p>In some patients with JEV infection, the presentation may be with a poliomyelitis-like acute flaccid paralysis due to anterior horn cell damage, without any alteration in consciousness [<a href="#rid22">22,23</a>]. After a brief febrile illness, paralysis occurs in one or more limbs, usually asymmetric and more common in the lower than upper limbs. In these patients, encephalitis develops subsequently in about 30 percent [<a href="#rid19">19</a>]. Patients with JEV infection can also present with Guillain Barré syndrome [<a href="#rid24">24</a>]. </p><p>Clinical signs associated with a poor prognosis include multiple prolonged seizures and raised intracranial pressure. Changes in the respiratory pattern, flexor and extensor posturing, and abnormalities of the pupillary and oculocephalic reflexes are also poor prognostic signs and may reflect brainstem encephalitis with or without transtentorial herniation [<a href="#rid21">21,25</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H6"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>The white blood cell count is moderately elevated in most patients, and hyponatremia may be observed due to the syndrome of inappropriate antidiuretic hormone secretion. Thrombocytopenia, mild anemia, and elevated hepatic enzymes may also occur but are relatively nonspecific laboratory features.</p><p>The cerebrospinal fluid (CSF) opening pressure is elevated in about 50 percent of patients. CSF findings are typically a mild to moderate pleocytosis of 10 to several hundred white blood cells/mm<sup>3</sup> with lymphocytic predominance, slightly elevated protein, and normal CSF to plasma glucose ratio. Early in disease, there may be no pleocytosis or neutrophils may predominate.</p><p class="headingAnchor" id="H7"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging is more sensitive than computed tomography scanning for detecting JEV-associated abnormalities such as changes in the thalamus, basal ganglia, midbrain, pons, and medulla [<a href="#rid26">26,27</a>]. Thalamic lesions are the most commonly described abnormality; although these can be highly specific for JE in the appropriate clinical context, they are not a very sensitive marker of JE (<a class="graphic graphic_diagnosticimage graphicRef65410" href="/d/graphic/65410.html" rel="external">image 1</a>) [<a href="#rid28">28</a>].</p><p>Electroencephalogram abnormalities may include theta and delta coma, burst suppression, epileptiform activity, and occasionally alpha coma [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Diagnostic testing</span><span class="headingEndMark"> — </span>JE is diagnosed serologically by detection of JEV-specific immunoglobin (Ig)M antibodies in CSF or serum by an enzyme-linked immunosorbent assay (ELISA). The presence of JEV-specific IgM antibodies in CSF confirms recent central nervous system infection. IgM antibody in serum is suggestive of JE but could indicate asymptomatic infection or recent JEV vaccination.</p><p>On admission to hospital, CSF antibodies are detectable in 70 to 90 percent of JE patients; JEV IgM is detectable in most CSF samples collected five to eight days after symptom onset. On admission to hospital, serum antibodies are detectable in about 60 to 70 percent of patients; serum antibodies are detectable in nearly all serum samples collected at least nine days after symptom onset [<a href="#rid29">29-32</a>]. If JE is suspected and acute samples are negative, a convalescent serum sample should be collected.</p><p>Important considerations for interpretation of serology results include vaccination history, date of onset of symptoms, and information regarding other flaviviruses known to circulate in the geographical area that may cross-react in serologic assays (such as dengue, Murray Valley encephalitis, or West Nile viruses). As serodiagnosis of flaviviral infections is not straightforward and cross-reactivity is common, samples positive by ELISA should be referred to a reference laboratory for confirmatory plaque reduction neutralization testing.</p><p>Virus isolation or detection of viral ribonucleic acid (RNA) with a nucleic acid amplification test (NAAT) can provide a definitive diagnosis, but positive results from CSF or blood are rare [<a href="#rid21">21,33,34</a>]. Because humans have low levels of transient viremia and high levels of neutralizing antibodies by the time distinctive clinical symptoms are recognized, virus isolation and NAATs are insensitive for the detection of JEV or JE viral RNA in blood or CSF. JEV isolates have been obtained postmortem from brain tissue [<a href="#rid31">31</a>].</p><p>United States health care providers should contact their state or local health department or the United States Centers for Disease Control and Prevention's (CDC's) Division of Vector-Borne Diseases in Colorado for assistance with diagnostic testing (telephone: 970-221-6400).</p><p class="headingAnchor" id="H10"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of JE includes other viral encephalitides, other central nervous system infections, para- or postinfectious causes, and noninfectious diseases [<a href="#rid25">25,35</a>]. Domestic arboviral infections should be considered if the patient could have been exposed to local arboviruses during the incubation period. In the United States, this may include La Crosse, St. Louis encephalitis, Eastern equine encephalitis, or Powassan viruses, among other arboviruses [<a href="#rid36">36</a>]. (See related topics.)</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of JE consists of supportive care with emphasis on control of intracranial pressure, maintenance of adequate cerebral perfusion pressure, seizure control, and prevention of secondary complications [<a href="#rid37">37</a>].</p><p>There is no specific antiviral treatment for JE. A randomized, placebo-controlled trial of oral <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> in 153 Indian children did not show any difference in outcome between the treatment and control groups [<a href="#rid38">38</a>]. Corticosteroids and interferon-alfa-2a did not improve outcome in controlled clinical trials [<a href="#rid39">39,40</a>]. Work is ongoing to investigate other potential antiviral agents [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H12"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Mortality among hospitalized patients is about 20 to 30 percent. Some deaths come after a short fulminant course while others occur after a prolonged period of coma [<a href="#rid1">1</a>].</p><p>Among JE survivors, long-term sequelae occur in at least 30 to 50 percent. Although the clinical condition of many JE patients improves after hospital discharge, deterioration in the months following acute illness may be observed in about 20 percent of patients [<a href="#rid15">15</a>]. The most common sequelae are upper and lower motor neuron weakness and cerebellar and extrapyramidal signs. Severe cognitive or language impairment, psychiatric problems, and recurrent seizures also occur. Among patients who appear to have recovered well, subtle sequelae such as learning or behavioral problems may be observed in about 50 percent [<a href="#rid19">19</a>].</p><p>There is limited information on JEV infection in pregnancy. In India, four miscarriages were reported among nine infected pregnant women; all of the women were in the first or second trimester of pregnancy [<a href="#rid17">17,43</a>]. JEV was isolated from one of the four aborted fetuses, suggesting that intrauterine transmission of JEV can occur.</p><p>Infection with JEV is thought to produce lifelong immunity.</p><p class="headingAnchor" id="H13"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Personal protective measures to prevent mosquito bites are important to reduce the risk of JE among travelers to endemic regions. In addition, JE vaccine provides substantial additional protection for travelers to high-risk settings (based on location, duration, season, accommodations, and activities) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Personal protective measures</span><span class="headingEndMark"> — </span>Measures include using insect repellent, permethrin-impregnated clothing, staying in screened or air-conditioned rooms, or sleeping under a bed net. (See  <a class="medical medical_review" href="/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>One JE vaccine is available in the United States: an inactivated Vero cell culture-derived vaccine (JE-VC; IXIARO) (<a class="graphic graphic_table graphicRef78205" href="/d/graphic/78205.html" rel="external">table 1</a>). JE-VC was licensed in 2009 for use in individuals ≥17 years and in 2013 for use in children 2 months through 16 years of age. An inactivated mouse brain-derived vaccine (JE-MB; JE-VAX) was used in the United States for almost 20 years following its licensure in 1992, but it is no longer available.</p><p>Other JE vaccines are manufactured and used in other countries but are not licensed for use in the United States. These include a live-attenuated chimeric virus vaccine, the live-attenuated SA 14-14-2 JE vaccine, inactivated Vero cell culture-derived vaccines, and inactivated mouse brain-derived vaccines. The recommended number of doses and schedule vary by vaccine and country.</p><p class="headingAnchor" id="H2867730"><span class="h3">Whom to vaccinate</span><span class="headingEndMark"> — </span>Most travelers to JE-endemic countries are at low risk for clinical JE. We are in agreement with the United States Advisory Committee on Immunization Practices (ACIP) which recommends JE vaccine for individuals moving to a JE-endemic country to take up residence, longer-term (eg, ≥1 month) travelers to JE-endemic areas, and frequent travelers to JE-endemic areas (<a class="graphic graphic_table graphicRef54113" href="/d/graphic/54113.html" rel="external">table 2</a>). Vaccination should be considered for shorter-term travelers with an increased risk of JEV exposure [<a href="#rid3">3</a>]. JE vaccine is not recommended for travelers with very low-risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JEV transmission season.</p><p>For most travelers to JE-endemic countries, the risk of developing JE disease is very low. Factors that increase the risk for JEV exposure include:</p><p class="bulletIndent1"><span class="glyph">●</span>Longer duration of travel</p><p class="bulletIndent1"><span class="glyph">●</span>Travel during the JEV transmission season</p><p class="bulletIndent1"><span class="glyph">●</span>Spending time in rural areas</p><p class="bulletIndent1"><span class="glyph">●</span>Participating in extensive outdoor activities</p><p class="bulletIndent1"><span class="glyph">●</span>Staying in an accommodation without air conditioning, screens, or bed nets</p><p></p><p>Health care providers should assess each traveler’s risk for mosquito exposure and JEV infection on the basis of their planned itinerary. The decision whether to vaccinate should be individualized and predicated on the risks related to the specific travel itinerary, the likelihood of future travel to JE-endemic countries, the high morbidity and mortality of JE, the availability of an effective vaccine, the possibility (but low probability) of serious adverse events after vaccination, and patient preference. </p><p class="headingAnchor" id="H347394509"><span class="h3">Immunogenicity and safety</span><span class="headingEndMark"> — </span>There are no efficacy data for JE-VC; the vaccine was licensed on the basis of its ability to induce JEV neutralizing antibodies as a surrogate for protection and safety evaluations [<a href="#rid3">3</a>]. JEV neutralizing antibody levels measured by plaque-reduction neutralization test are thought to be a reliable surrogate for efficacy.</p><p class="headingAnchor" id="H2867757"><span class="h4">Adults</span><span class="headingEndMark"> — </span>In a noninferiority immunogenicity study comparing JE-VC (two-dose schedule; 365 adults) with JE-MB (three-dose schedule; 370 adults), seroconversion rates at 28 days after the last dose were comparable (96 versus 94 percent, respectively) [<a href="#rid44">44,45</a>]. Among adults aged ≥65 years, seroprotection rates are lower; 65 percent of individuals in this age group have seroprotection at 42 days after the two-dose primary series [<a href="#rid46">46</a>].</p><p>In one observational study evaluating long-term seroprotection among adults 6 years following a booster dose of JE-VC at 15 months, seroprotection was observed among 96 percent of individuals [<a href="#rid47">47</a>]. Seroprotection against JE-VC may be enhanced among individuals who are also vaccinated against tickborne encephalitis [<a href="#rid48">48</a>].</p><p>Studies evaluating individuals receiving JE-VC or placebo adjuvant have described comparable rates of local and systemic reactions [<a href="#rid45">45,49</a>]. In a study evaluating 2650 individuals who received JE-VC or placebo adjuvant, the frequency of injection site reaction was similar in both groups (about 55 percent overall; 3 percent severe) [<a href="#rid45">45,49</a>]. Pain and tenderness were the most common reactions. Overall, about 60 percent of subjects reported a systemic adverse event; headache, myalgias, fatigue, and an influenza-like illness were each reported at a rate of &gt;10 percent. The rates of serious adverse events following immunization were also similar in the vaccine and the placebo groups (0.5 and 0.9 percent). A publication reporting findings from postmarketing surveillance data suggested a good safety profile for JE-VC, consistent with findings from prelicensure clinical trials [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H2867763"><span class="h4">Children</span><span class="headingEndMark"> — </span>The largest pediatric trial of JE-VC was conducted in children aged 2 months through 17 years in the Philippines [<a href="#rid51">51,52</a>]. Among 385 children vaccinated with JE-VC and evaluated for seroprotection, 384 had protective antibodies 28 days following the second dose. At six months following completion of the series, protective antibodies were present in 88 percent (134 out of 152) of children aged two months to two years (CI 82-92 percent), and 95 percent (224 out of 237) of children aged 3 to 17 years (CI 91-97 percent) [<a href="#rid3">3</a>]. In another pediatric trial among 23 children in India aged between 1 and 3 years, 96 percent (CI 87-100 percent) had protective antibodies at 28 days after two doses of JE-VC [<a href="#rid53">53</a>]. In an observational study of children from nonendemic countries, all 62 children had protective neutralizing antibodies at 28 days [<a href="#rid51">51,54</a>].</p><p>The incidence of adverse events due to JE-VC appear to be similar to those observed with the comparison vaccines used in the clinical trials, including pneumococcal conjugate vaccine and <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> [<a href="#rid3">3</a>]. In the clinical trial in the Philippines, 9 percent (122 out of 1411) of JE-VC recipients had fever (≥38°C) within seven days after the first dose, and 6 percent (84 out of 1405) had fever within seven days after the second dose. Fewer than 1 percent had urticaria, hypersensitivity reaction, or febrile seizures [<a href="#rid3">3,51</a>].</p><p class="headingAnchor" id="H347394526"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span>For adults 18 to 65 years of age, the primary immunization schedule for JE-VC is two doses administered intramuscularly 7 to 28 days apart. For children 2 months to &lt;18 years of age and for adults &gt;65 years of age, the primary immunization schedule is two doses administered intramuscularly on days 0 and 28. The two-dose series should be completed at least one week prior to travel.</p><p>For adults and children ≥3 years, each dose is 0.5 mL; for children aged 2 months to 2 years of age, each dose is 0.25 mL. For adults and children, a booster dose should be given if the primary series of JE-VC was administered ≥1 year previously and ongoing exposure or re-exposure to JEV is expected [<a href="#rid3">3</a>]. No data are available on the response to a booster dose administered &gt;2 years after the primary series. </p><p>A severe allergic reaction after a previous dose of JE-VC, any other JE vaccine, or any component of JE-VC is a contraindication to administration of a subsequent dose. JE-VC contains <a class="drug drug_general" data-topicid="9831" href="/d/drug information/9831.html" rel="external">protamine sulfate</a>, which is known to cause hypersensitivity reactions in some individuals; it does not contain gelatin or murine proteins [<a href="#rid55">55</a>]. The risk of hypersensitivity or neurologic adverse events with JE-VC is probably lower than that with JE-MB, although the possibility of rare adverse events cannot be excluded. No studies of JE-VC in pregnant women have been conducted. Therefore, administration of JE-VC to pregnant women usually should be deferred. However, pregnant women who must travel to an area where risk for JEV infection is high should be vaccinated when the theoretical risk for immunization is outweighed by the risk for infection.</p><p>Data on use of JE-VC as a booster dose after a primary series with the mouse brain–derived inactivated JE vaccine (JE-MB) are limited. Three studies have investigated the use of JE-VC as a booster dose after a primary series with JE-MB; two studies were performed among United States military personnel and one was conducted at two European travel clinics [<a href="#rid3">3,56,57</a>]. In one United States military study and the European study, among adults previously vaccinated with a primary series of JE-MB, a single dose of JE-VC adequately boosted neutralizing antibody levels (measured at 4 to 8 weeks after the booster dose). A second study among United States military personnel investigated longer term protection, the immunologic response at 12 to 23 months following one dose of JE-VC in adults previously vaccinated with ≥3 doses of JE-MB was noninferior to the response following two doses of JE-VC in JE vaccine-naïve adults [<a href="#rid3">3</a>]. Among 19 European study participants available for longer-term follow up, 89 to 100 percent had protective neutralizing antibodies against different genotypes of JEV a mean of 2 years following the booster dose [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H4033665678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109959.html" rel="external">"Society guideline links: Infectious encephalitis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is the most important cause of viral encephalitis in Asia based on its frequency and severity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>About 68,000 cases of Japanese encephalitis are estimated to occur each year. However, for travelers, the risk is low. Fewer than 1 percent of JEV infections results in symptomatic neuroinvasive disease. However, when neurological disease does occur, it is usually a very severe disease with a high case-fatality rate and neurological sequelae in 30 to 50 percent of survivors. (See <a class="local">'Introduction'</a> above and <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In endemic areas, JE typically affects children &lt;15 years of age; by early adulthood, the majority of the population has protective immunity following natural exposure to JEV as a result of ongoing environmental transmission. Among immunologically naïve travelers visiting endemic regions, the disease can affect individuals at any age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>JEV is transmitted in an enzootic cycle involving mosquitoes and vertebrate-amplifying hosts, primarily pigs and wading birds. Humans are incidental and dead-end hosts in the JEV transmission cycle as they do not develop sufficiently high viremia to infect feeding mosquitoes. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most commonly recognized clinical presentation of JEV infection is acute encephalitis. Milder forms of disease such as aseptic meningitis or nonspecific febrile illness with headache also occur. Seizures (usually generalized tonic-clonic) are very common, especially among children. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>JE is diagnosed serologically by detection of JEV-specific immunoglobin (Ig)M antibody in cerebrospinal fluid (CSF) or serum by an enzyme-linked immunosorbent assay. The presence of JEV-specific IgM antibodies in CSF confirms recent central nervous system infection. IgM antibody in serum is suggestive of JE but could indicate asymptomatic infection or recent JE vaccination. (See <a class="local">'Diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no specific antiviral treatment for JE. Treatment consists of supportive care with emphasis on control of intracranial pressure, maintenance of adequate cerebral perfusion pressure, seizure control, and prevention of secondary complications. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Precautions to reduce the risk of JE among travelers to endemic regions include personal protective measures to prevent mosquito bites. For some travelers who will be in a high-risk setting (based on location, duration, season, accommodations, and activities), JE vaccine may further reduce the risk of infection. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One JE vaccine is available in the United States: an inactivated Vero cell culture-derived vaccine (JE-VC; IXIARO). (See <a class="local">'Vaccination'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The editorial staff at UpToDate would like to acknowledge Marc Fischer, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res 2003; 61:103.</a></li><li class="breakAll">Mackenzie JS, Williams DT, Smith DW. Japanese encephalitis virus: The geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas. In: Emerging Viruses in Human Populations, Tabor E (Ed), Elsevier, 2007.</li><li><a class="nounderline abstract_t">Hills SL, Walter EB, Atmar RL, et al. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2019; 68:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Japanese encephalitis in two children--United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:276.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Japanese Encephalitis. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/japanese-encephalitis (Accessed on July 29, 2019).</li><li class="breakAll">Halstead SB, Hills SL, Dubischar K. Japanese encephalitis vaccines. In: Vaccines, 7th ed, Plotkin SA, Orenstein WA, Offit PA, Edwards KM (Eds), Elsevier, 2017.</li><li><a class="nounderline abstract_t">van den Hurk AF, Skinner E, Ritchie SA, Mackenzie JS. The Emergence of Japanese Encephalitis Virus in Australia in 2022: Existing Knowledge of Mosquito Vectors. Viruses 2022; 14.</a></li><li><a class="nounderline abstract_t">Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002; 267:11.</a></li><li><a class="nounderline abstract_t">Arai S, Matsunaga Y, Takasaki T, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008; 61:333.</a></li><li><a class="nounderline abstract_t">Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992; 14:197.</a></li><li><a class="nounderline abstract_t">Ompusunggu S, Hills SL, Maha MS, et al. Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. Am J Trop Med Hyg 2008; 79:963.</a></li><li><a class="nounderline abstract_t">Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000; 18 Suppl 2:1.</a></li><li><a class="nounderline abstract_t">Wu YC, Huang YS, Chien LJ, et al. The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. Am J Trop Med Hyg 1999; 61:78.</a></li><li><a class="nounderline abstract_t">van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009; 54:17.</a></li><li><a class="nounderline abstract_t">Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997-2005. Clin Infect Dis 2008; 47:458.</a></li><li><a class="nounderline abstract_t">Cheng VCC, Sridhar S, Wong SC, et al. Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China. Emerg Infect Dis 2018; 24.</a></li><li><a class="nounderline abstract_t">Chaturvedi UC, Mathur A, Chandra A, et al. Transplacental infection with Japanese encephalitis virus. J Infect Dis 1980; 141:712.</a></li><li><a class="nounderline abstract_t">Qi ZL, Sun LY, Bai J, et al. Japanese encephalitis following liver transplantation: A rare case report. World J Clin Cases 2020; 8:337.</a></li><li><a class="nounderline abstract_t">Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000; 68:405.</a></li><li><a class="nounderline abstract_t">LINCOLN AF, SIVERTSON SE. Acute phase of Japanese B encephalitis; two hundred and one cases in American soldiers, Korea, 1950. J Am Med Assoc 1952; 150:268.</a></li><li><a class="nounderline abstract_t">Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 2002; 125:1084.</a></li><li><a class="nounderline abstract_t">Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet 1998; 351:1094.</a></li><li><a class="nounderline abstract_t">Chung CC, Lee SS, Chen YS, et al. Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. Infection 2007; 35:30.</a></li><li><a class="nounderline abstract_t">Wang G, Li H, Yang X, et al. Guillain-Barré Syndrome Associated with JEV Infection. N Engl J Med 2020; 383:1188.</a></li><li><a class="nounderline abstract_t">Solomon T. Flavivirus encephalitis. N Engl J Med 2004; 351:370.</a></li><li><a class="nounderline abstract_t">Maschke M, Kastrup O, Forsting M, Diener HC. Update on neuroimaging in infectious central nervous system disease. Curr Opin Neurol 2004; 17:475.</a></li><li><a class="nounderline abstract_t">Wang HS. Comparison of magnetic resonance imaging abnormalities in Japanese encephalitis and acute necrotizing encephalopathy of childhood. Arch Neurol 2004; 61:1149.</a></li><li><a class="nounderline abstract_t">Dung NM, Turtle L, Chong WK, et al. An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis. J Neurol 2009; 256:2052.</a></li><li><a class="nounderline abstract_t">Solomon T, Thao TT, Lewthwaite P, et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ 2008; 86:178.</a></li><li><a class="nounderline abstract_t">Kari K, Liu W, Gautama K, et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med 2006; 4:8.</a></li><li><a class="nounderline abstract_t">Burke DS, Lorsomrudee W, Leake CJ, et al. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg 1985; 34:1203.</a></li><li><a class="nounderline abstract_t">Chanama S, Sukprasert W, Sa-ngasang A, et al. Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients. Jpn J Infect Dis 2005; 58:294.</a></li><li><a class="nounderline abstract_t">Swami R, Ratho RK, Mishra B, Singh MP. Usefulness of RT-PCR for the diagnosis of Japanese encephalitis in clinical samples. Scand J Infect Dis 2008; 40:815.</a></li><li><a class="nounderline abstract_t">Kuwayama M, Ito M, Takao S, et al. Japanese encephalitis virus in meningitis patients, Japan. Emerg Infect Dis 2005; 11:471.</a></li><li><a class="nounderline abstract_t">Solomon T, Hart IJ, Beeching NJ. Viral encephalitis: a clinician's guide. Pract Neurol 2007; 7:288.</a></li><li><a class="nounderline abstract_t">Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg 2008; 79:974.</a></li><li><a class="nounderline abstract_t">Tiroumourougane SV, Raghava P, Srinivasan S. Japanese viral encephalitis. Postgrad Med J 2002; 78:205.</a></li><li><a class="nounderline abstract_t">Kumar R, Tripathi P, Baranwal M, et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009; 48:400.</a></li><li><a class="nounderline abstract_t">Hoke CH Jr, Vaughn DW, Nisalak A, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 1992; 165:631.</a></li><li><a class="nounderline abstract_t">Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361:821.</a></li><li><a class="nounderline abstract_t">Rayamajhi A, Nightingale S, Bhatta NK, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One 2015; 10:e0122608.</a></li><li><a class="nounderline abstract_t">Turtle L, Solomon T. Japanese encephalitis - the prospects for new treatments. Nat Rev Neurol 2018; 14:298.</a></li><li><a class="nounderline abstract_t">Mathur A, Tandon HO, Mathur KR, et al. Japanese encephalitis virus infection during pregnancy. Indian J Med Res 1985; 81:9.</a></li><li><a class="nounderline abstract_t">Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847.</a></li><li class="breakAll">Japanese Encephalitis Vaccine, Inactivated, Adsorbed (IXIARO). Package insert (commercial). http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm (Accessed on May 19, 2011).</li><li><a class="nounderline abstract_t">Cramer JP, Dubischar K, Eder S, et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. Vaccine 2016; 34:4579.</a></li><li><a class="nounderline abstract_t">Paulke-Korinek M, Kollaritsch H, Kundi M, et al. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine 2015; 33:3600.</a></li><li><a class="nounderline abstract_t">Taucher C, Kollaritsch H, Dubischar KL. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. Vaccine 2019; 37:2529.</a></li><li><a class="nounderline abstract_t">Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198:493.</a></li><li><a class="nounderline abstract_t">Rabe IB, Miller ER, Fischer M, Hills SL. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012. Vaccine 2015; 33:708.</a></li><li class="breakAll">US Food and Drug Administration. Clinical review: Ixiaro. Silver Spring, MD: Food and Drug Administration; 2013. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm354012.pdf (Accessed on November 19, 2013).</li><li><a class="nounderline abstract_t">Dubischar KL, Kadlecek V, Sablan JB, et al. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region. Pediatr Infect Dis J 2017; 36:898.</a></li><li><a class="nounderline abstract_t">Kaltenböck A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834.</a></li><li><a class="nounderline abstract_t">Jelinek T, Cromer MA, Cramer JP, et al. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study. Travel Med Infect Dis 2018; 22:18.</a></li><li class="breakAll">US Food and Drug Administration. Product approval information [package insert]. Ixiaro (Japanese encephalitis virus vaccine inactivated). Intercell Biomedical, Livingston, United Kingdom. http://www.fda.gov/cber/label/ixiarocommercialLB.pdf (Accessed on July 31, 2009).</li><li><a class="nounderline abstract_t">Erra EO, Askling HH, Rombo L, et al. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines. Clin Infect Dis 2012; 55:825.</a></li><li><a class="nounderline abstract_t">Woolpert T, Staples JE, Faix DJ, et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 2012; 30:3090.</a></li><li><a class="nounderline abstract_t">Erra EO, Askling HH, Yoksan S, et al. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study. Vaccine 2013; 32:119.</a></li></ol></div><div id="topicVersionRevision">Topic 3034 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14714431" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14714431" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31518342" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21389931" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Japanese encephalitis in two children--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21389931" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Japanese encephalitis in two children--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21389931" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Japanese encephalitis in two children--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35746679" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Emergence of Japanese Encephalitis Virus in Australia in 2022: Existing Knowledge of Mosquito Vectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12082986" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Japanese encephalitis virus: ecology and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806337" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1337744" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The epidemiology of Japanese encephalitis: prospects for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052312" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821969" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The epidemiology of Japanese encephalitis on Taiwan during 1966-1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067628" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ecology and geographical expansion of Japanese encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616397" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29043965" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6248601" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transplacental infection with Japanese encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32047783" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Japanese encephalitis following liver transplantation: A rare case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727474" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14955436" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute phase of Japanese B encephalitis; two hundred and one cases in American soldiers, Korea, 1950.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960897" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660579" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Poliomyelitis-like illness due to Japanese encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297587" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32937054" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guillain-BarréSyndrome Associated with JEV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269317" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Flavivirus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Update on neuroimaging in infectious central nervous system disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262755" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of magnetic resonance imaging abnormalities in Japanese encephalitis and acute necrotizing encephalopathy of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633907" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18368204" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A cohort study to assess the new WHO Japanese encephalitis surveillance standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16603053" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010752" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fatal outcome in Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249624" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618334" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Usefulness of RT-PCR for the diagnosis of Japanese encephalitis in clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757569" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Japanese encephalitis virus in meningitis patients, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17885268" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Viral encephalitis: a clinician's guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052314" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11930023" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Japanese viral encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19143532" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1313068" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642049" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25886645" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29697099" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Japanese encephalitis - the prospects for new treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2985501" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Japanese encephalitis virus infection during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061060" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061060" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27460550" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO®in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036947" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962094" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO®in healthy adults: A five year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18588481" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25498208" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25498208" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430748" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19857447" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549036" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549036" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696017" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22406277" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24176496" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
